Does haptoglobin genotype affect early onset of diabetic retinopathy in patients with type 2 diabetes?

Retina

Volumn 31, Issue 8, 2011, Pages 1574-1580

  Goldenberg Cohen, Nitza ^a,b   Gabbay, Merav ^c,d   Dratviman Storobinsky, Olga ^d   Reich, Ehud ^b   Axer Siegel, Ruth ^b,d   Weinberger, Dov ^b,d   Gabbay, Uri ^b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

case control study; diabetic retinopathy; DM2; early PDR; haptoglobin genotype; Hp1 1; Hp2 1; Hp2 2; proliferative diabetic retinopathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; HAPTOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SEX DIFFERENCE; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; OPHTHALMOSCOPY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 80052453253     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31820a68f8     Document Type: Article

References (52)

1. Ciulla TA, Harris A, Latkany P, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 2002;80: 468-477. (Pubitemid 35243850)
2. Frank KJ, Dieckert JP. Diabetic eye disease: A primary care perspective. South Med J 1996;89:463-470. (Pubitemid 26142542)
3. Aylward GW. Progressive changes in diabetics and their management. Eye 2005;19:1115-1118. (Pubitemid 41823771)
4. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350: 48-58. (Pubitemid 38032183)
5. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007;2007:43603.
6. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254-1264.
7. Manaviat MR, Rashidi M, Afkhami-Ardekani M. Four years incidence of diabetic retinopathy and effective factors on its progression in type II diabetes. Eur J Ophthalmol 2008;18: 572-577.
8. Yam JC, Kwok AK. Update on the treatment of diabetic retinopathy. Hong Kong Med J 2007;13:46-60. (Pubitemid 46482034)
9. Xie XW, Xu L,Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol 2008;246:1519-1526.
10. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009;58:2137-2147.
11. Melamed-Frank M, Lache O, Enav BI, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001;98:3693-3698.
12. Tseng CF, Lin CC, Huang HY, Liu HC, Mao SJ. Antioxidant role of human haptoglobin. Proteomics 2004;4:2221-2228. (Pubitemid 39025321)
13. Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005;1:19-28.
14. Nakhoul FM, Marsh S, Hochberg I, et al. Haptoglobin genotype as a risk factor for diabetic retinopathy. JAMA 2000;284:1244-1245.
15. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-1600. (Pubitemid 26354735)
16. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005;96:435-441. (Pubitemid 40354537)
17. Levy AP, Asleh R, Blum S, et al. Haptoglobin: Basic and clinical aspects. Antioxid Redox Signal 2010;12:293-304.
18. Koch W, Latz W, Eichinger M, et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002;48:1377-1382. (Pubitemid 34925770)
19. Chandy A, Pawar B, John M, Isaac R. Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications. Saudi J Kidney Dis Transpl 2008;19:924-928.
20. Liew G, Wong TY, Mitchell P, Cheung N, Wang JJ. Retinopathy predicts coronary heart disease mortality. Heart 2009;95:391-394.
21. Jeganathan VS, Cheung N, Wong Y. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med 2008;25:882; author reply 882-883.
22. Reaven PD, Emanuele N, Moritz T, et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2008;31:952-957.
23. Van Vlierberghe H, Langlois M, Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 2004;345:35-42. (Pubitemid 38749169)
24. Asaf R, Blum S, Roguin A, et al. Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice. Cardiovasc Diabetol 2009;8:29.
25. Asleh R, Blum S, Kalet-Litman S, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008;57:2794-2800.
26. Awadallah SM, Saleh SA, Abu Shaqra QM, Hilow H. Association of haptoglobin phenotypes with markers of diabetic nephropathy in type 2 diabetes mellitus. J Diabetes Complications 2008;22:384-388.
27. Bessa SS, Hamdy SM, Ali EM. Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: An Egyptian study. Eur J Intern Med 2007;18: 489-495. (Pubitemid 47379544)
28. Koda Y, Soejima M, Yamagishi S, et al. Haptoglobin genotype and diabetic microangiopathies in Japanese diabetic patients. Diabetologia 2002;45:1039-1040. (Pubitemid 34762201)
29. Levy AP. Haptoglobin: A major susceptibility gene for diabetic cardiovascular disease. Isr Med Assoc J 2004;6:308-310. (Pubitemid 38628346)
30. Moreno PR, Purushothaman KR, Purushothaman M, et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008;52:1049-1051.
31. Nakhoul FM, Miller-Lotan R, Awaad H, et al. Hypothesis- haptoglobin genotype and diabetic nephropathy. Nat Clin Pract Nephrol 2007;3:339-344. (Pubitemid 46834869)
32. Quaye IK. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008;102:735-742.
33. Quaye IK, Ababio G, Amoah AG. Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. J Atheroscler Thromb 2006;13:90-94.
34. Shor M, Boaz M, Gavish D, et al. Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus. Am J Cardiol 2007;100:1767-1770. (Pubitemid 350234796)
35. Wobeto VP, Garcia PM, Zaccariotto TR, Sonati Mde F. Haptoglobin polymorphism and diabetic nephropathy in Brazilian diabetic patients. Ann Hum Biol 2009;36: 437-441.
36. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: A determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57:1702-1706.
37. Levy AP, Larson MG, Corey D, et al. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis 2004;172:361-365. (Pubitemid 38167547)
38. Conway BR, Savage DA, Brady HR, Maxwell AP. Association between haptoglobin gene variants and diabetic nephropathy: Haptoglobin polymorphism in nephropathy susceptibility. Nephron Exp Nephrol 2007;105:e75-e79. (Pubitemid 46438566)
39. Blum S, Asaf R, Guetta J, et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. J Am Coll Cardiol 2007;49:82-87. (Pubitemid 46026894)
40. Levy AP, Roguin A, Hochberg I, et al. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med 2000;343:969-970.
41. Miller-Lotan R, Miller B, Nakhoul F, et al. Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev 2007;23:152-156.
42. Obrosova IG, Minchenko AG, Marinescu V, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001;44:1102-1110. (Pubitemid 32835501)
43. Wobeto VP, Rosim ET, Melo MB, Calliari LE, Sonati Mde F. Haptoglobin polymorphism and diabetic retinopathy in Brazilian patients. Diabetes Res Clin Pract 2007;77:385-388. (Pubitemid 47214585)
44. Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2009;103:1364-1367.
45. Barbosa J, Segall M, Rich S. Genetic relationships between type I and type II diabetes mellitus. Adv Exp Med Biol 1988; 246:127-130.
46. Rich SS, Panter SS, Goetz FC, et al. Shared genetic susceptibility of type 1 (insulin-dependent) and type 2 (noninsulin- dependent) diabetes mellitus: Contributions of HLA and haptoglobin. Diabetologia 1991;34:350-355.
47. Bek T, Lund-Andersen H, Hansen AB, et al. The prevalence of diabetic retinopathy in patients with screen-detected type 2 diabetes in Denmark: The ADDITION study. Acta Ophthalmol 2009;87:270-274.
48. Goh PP. Status of diabetic retinopathy among diabetics registered to the Diabetic Eye Registry, National Eye Database, 2007. Med J Malaysia 2008;63(Suppl C):24-28.
49. Salti HI, Nasrallah MP, Taleb NM, et al. Prevalence and determinants of retinopathy in a cohort of Lebanese type II diabetic patients. Can J Ophthalmol 2009;44:308-313.
50. Rubino A, Rousculp MD, Davis K,Wang J, Gira A. Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. Prim Care Diabetes 2007;1:75-80.
51. Sloan FA, Belsky D, Ruiz D Jr, Lee P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons, 1994-2005. Arch Ophthalmol 2008;126:1548-1553.
52. Awadallah S, Hamad M. The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent. Cytobios 2000;101:145-150.